Ovid Therapeutics (OVID) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$25.6 million.
- Ovid Therapeutics' Enterprise Value rose 5917.37% to -$25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year increase of 5917.37%. This contributed to the annual value of -$53.1 million for FY2024, which is 4985.07% up from last year.
- Per Ovid Therapeutics' latest filing, its Enterprise Value stood at -$25.6 million for Q3 2025, which was up 5917.37% from -$38.3 million recorded in Q2 2025.
- Over the past 5 years, Ovid Therapeutics' Enterprise Value peaked at -$25.6 million during Q3 2025, and registered a low of -$233.1 million during Q1 2021.
- Moreover, its 5-year median value for Enterprise Value was -$105.8 million (2023), whereas its average is -$116.8 million.
- In the last 5 years, Ovid Therapeutics' Enterprise Value crashed by 41437.56% in 2021 and then surged by 5917.37% in 2025.
- Ovid Therapeutics' Enterprise Value (Quarter) stood at -$187.8 million in 2021, then soared by 31.31% to -$129.0 million in 2022, then grew by 17.96% to -$105.8 million in 2023, then surged by 49.85% to -$53.1 million in 2024, then surged by 51.76% to -$25.6 million in 2025.
- Its Enterprise Value was -$25.6 million in Q3 2025, compared to -$38.3 million in Q2 2025 and -$43.0 million in Q1 2025.